News | January 28, 2007

Imaging, Technology Innovations Shared with Bypass Surgeons

Jan. 29, 2007 — Novadaq Technologies Inc. and Apple Inc. presented new technologies to about 100 heart surgeons Sunday evening, Jan. 28, in San Diego. Gathering members of the Society of Thoracic Surgeons, whose annual meeting is convening at the San Diego Convention Center through Jan. 31, the program featured Novadaq’s SPY Intra-operative Imaging System, a real-time visual imaging device for use during heart bypass surgery. Apple shared how its technologies are being used in medicine and how the iPod is facilitating personal and portable medical media.

"We are delighted that Apple co-sponsored this event with Novadaq," said Dr. Arun Menawat, President and Chief Executive Officer Novadaq Technologies Inc. "Novadaq's innovations are providing medical imaging for the operating room to improve clinical outcomes and Apple is the leader of innovation in the personal computing industry. It's a synergistic fit between technologies and a perfect opportunity for cardiac surgeons to see and participate in the imaging revolution."

Speakers presented on how new technology is helping doctors use imaging in new ways to help patients and educated cardiac surgeons about Apple technology in medicine.

The SPY System is the first and only fluorescent imaging system FDA cleared for use in coronary artery bypass surgery. SPY enables cardiac surgeons to simply and efficiently assess the quality of blood flow through the heart during surgery.

Related Content

Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Overlay Init